Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application
Launched by UNIVERSITY OF ULM · Jan 22, 2024
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
According to the recommendations, IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight. 28-day mortality and 30-day time course of leukocyte counts and serum concentrations of C-reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL-6) and ferritin in 4 patient groups, i. e., treated without (N) or with casirivimab / imdevimab (C) or tocilizumab (T),...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of COVID-19
- • CoV-2 delta-variant
- • critically ill patients
- • ICU
- Exclusion Criteria:
- • tuberculosis
- • active hepatitis
- • HIV
About University Of Ulm
The University of Ulm is a leading academic institution located in Germany, renowned for its commitment to cutting-edge research and innovation in the fields of medicine and health sciences. As a clinical trial sponsor, the university leverages its robust network of researchers and clinical experts to advance medical knowledge and improve patient outcomes. With a focus on interdisciplinary collaboration, the University of Ulm conducts comprehensive clinical studies that adhere to the highest ethical standards and regulatory guidelines. Through its research initiatives, the university aims to contribute significantly to the development of new therapies and treatment modalities, fostering a deeper understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ulm, , Germany
Patients applied
Trial Officials
Manfred Weiss, MD
Principal Investigator
University of Ulm
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported